192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma

Similar Items

• Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
  by: Ricciuti, Biagio, et al.
  Published: (2020)
• 246 Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups
  by: Mark Awad, et al.
  Published: (2020-11-01)
• Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications
  by: Hyesun Park, et al.
  Published: (2023-01-01)
• Immunophenotypic profiles and prognosis for colorectal mucinous adenocarcinomas are dependent on anatomic location
  by: Chirag Patel, et al.
  Published: (2023-04-01)
• Clinicopathological and genomic features of breast mucinous carcinoma
  by: Kebin Lu, et al.
  Published: (2020-10-01)